Global Partners LP
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Global Partners LP Global Partners LP (NYSE: GLP), a master limited partnership founded in 2005 with roots tracing back to 1933, serves as a leading midstream logistics and marketing company headquartered in Waltham, Massachusetts. The company engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates including diesel and heating oil, residual oil, renewable fuels such as biodiesel and ethanol, crude oil, propane, natural gas, and bunker fuel to wholesalers, retailers, gasoline station operators, sub-jobbers, commercial and industrial end-users, and public sector customers; it operates through three segments—Wholesale, which supplies branded and unbranded gasoline, home heating oil, kerosene, and residual oil via railcars, barges, trucks, and pipelines; Gasoline Distribution and Station Operations (GDSO), which distributes fuels to over 1,700 owned, leased, or supplied retail locations featuring convenience stores, prepared foods, car washes, lottery, and ATM services primarily across Northeast states, the Mid-Atlantic, and Texas; and Commercial, which delivers custom-blended fuels and energy products with a focus on the Northeast U.S. Global maintains dedicated storage at 54 liquid energy terminals connected to rail, pipeline, and marine assets spanning from Maine to Florida and into the U.S. Gulf States, while offering low-carbon solutions like GlobalGLO to support carbon footprint reduction. In recent developments, Global Partners LP completed the acquisition of a 959,730-barrel liquid energy terminal in East Providence, Rhode Island, from ExxonMobil Oil Corporation in November 2024, enhancing gasoline infrastructure, truck rack capacity, and supply optionality for its Northeast retail and marketing operations while adding surplus real estate for future development; the company also issued $450 million in senior unsecured notes due 2033 in June 2025, co-issued with GLP Finance Corp. and guaranteed by subsidiaries, to bolster its capital structure amid ongoing terminal expansions and diversification into renewable fuels.
Oil's 31% Q2 Selloff Opens the Door to 3 Strong Buy Stocks
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program
Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years
Global Partners LP Announces Full Redemption of Series B Fixed Rate Cumulative Redeemable Perpetual Preferred Units
Citi says Wegovy pill outpacing rivals as oral GLP-1 race heats up
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
GLP-1s linked to smell and taste impairment in diabetes patients
Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule
Walgreens Pharmacists Help Medicare Patients Navigate New Access to GLP‑1 Medications
Bank sees structural strength in GLP-1 market as obesity drives demand
Global Partners (GLP) Surges 6.9%: Is This an Indication of Further Gains?
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?